Anabolic Steroid Control Act of 2004
PL 108-358 (S.2195), enacted 10/22/2004

118 STAT. 1661
PUBLIC LAW 108–358—OCT. 22, 2004
Public Law 108–358
108th Congress
An Act
To amend the Controlled Substances Act to clarify the definition of anabolic steroids
and to provide for research and education activities relating to steroids and
steroid precursors.
Be it enacted by the Senate and House of Representatives of
the United States of America in Congress assembled,
SECTION 1. SHORT TITLE.
This Act may be cited as the ‘‘Anabolic Steroid Control Act
of 2004’’.
SEC. 2. AMENDMENTS TO THE CONTROLLED SUBSTANCES ACT.
(a) DEFINITIONS.—Section 102 of the Controlled Substances Act
(21 U.S.C. 802) is amended—
(1) in paragraph (41)—
(A) by realigning the margin so as to align with para-
graph (40); and
(B) by striking subparagraph (A) and inserting the
following:
‘‘(A) The term ‘anabolic steroid’ means any drug or hormonal
substance, chemically and pharmacologically related to testosterone
(other 
than 
estrogens, 
progestins, 
corticosteroids, 
and
dehydroepiandrosterone), and includes—
‘‘(i) androstanediol—
‘‘(I) 3β,17β-dihydroxy-5α-androstane; and
‘‘(II) 3α,17β-dihydroxy-5α-androstane;
‘‘(ii) androstanedione (5α-androstan-3,17-dione);
‘‘(iii) androstenediol—
‘‘(I) 1-androstenediol (3β,17β-dihydroxy-5α-androst-1-
ene);
‘‘(II) 1-androstenediol (3α,17β-dihydroxy-5α-androst-1-
ene);
‘‘(III) 
4-androstenediol 
(3β,17β-dihydroxy-androst-4-
ene); and
‘‘(IV) 
5-androstenediol 
(3β,17β-dihydroxy-androst-5-
ene);
‘‘(iv) androstenedione—
‘‘(I) 1-androstenedione ([5α]-androst-1-en-3,17-dione);
‘‘(II) 4-androstenedione (androst-4-en-3,17-dione); and
‘‘(III) 5-androstenedione (androst-5-en-3,17-dione);
‘‘(v) bolasterone (7α,17α-dimethyl-17β-hydroxyandrost-4-en-
3-one);
‘‘(vi) boldenone (17β-hydroxyandrost-1,4,-diene-3-one);
‘‘(vii) calusterone (7β,17α-dimethyl-17β-hydroxyandrost-4-
en-3-one);
21 USC 801 note.
Anabolic Steroid
Control Act of
2004.
Oct. 22, 2004
[S. 2195]
VerDate 11-MAY-2000
08:28 Nov 10, 2005
Jkt 029194
PO 00000
Frm 00525
Fmt 6580
Sfmt 6581
C:\STATUTES\2004\29194PT2.001
APPS10
PsN: 29194PT2
118 STAT. 1662
PUBLIC LAW 108–358—OCT. 22, 2004
‘‘(viii) clostebol (4-chloro-17β-hydroxyandrost-4-en-3-one);
‘‘(ix) 
dehydrochloromethyltestosterone 
(4-chloro-17β-
hydroxy-17α-methyl-androst-1,4-dien-3-one);
‘‘(x) >1-dihydrotestosterone (a.k.a. ‘1-testosterone’) (17β-
hydroxy-5α-androst-1-en-3-one);
‘‘(xi) 4-dihydrotestosterone (17β-hydroxy-androstan-3-one);
‘‘(xii) drostanolone (17β-hydroxy-2α-methyl-5α-androstan-3-
one);
‘‘(xiii) ethylestrenol (17α-ethyl-17β-hydroxyestr-4-ene);
‘‘(xiv) 
fluoxymesterone 
(9-fluoro-17α-methyl-11β,17β-
dihydroxyandrost-4-en-3-one);
‘‘(xv) 
formebolone 
(2-formyl-17α-methyl-11α,17β-
dihydroxyandrost-1,4-dien-3-one);
‘‘(xvi) furazabol (17α-methyl-17β-hydroxyandrostano[2,3-c]-
furazan);
‘‘(xvii) 13β-ethyl-17α-hydroxygon-4-en-3-one;
‘‘(xviii) 4-hydroxytestosterone (4,17β-dihydroxy-androst-4-
en-3-one);
‘‘(xix) 4-hydroxy-19-nortestosterone (4,17β-dihydroxy-estr-4-
en-3-one);
‘‘(xx) mestanolone (17α-methyl-17β-hydroxy-5α-androstan-
3-one);
‘‘(xxi) mesterolone (1α-methyl-17β-hydroxy-[5α]-androstan-
3-one);
‘‘(xxii) methandienone (17α-methyl-17β-hydroxyandrost-1,4-
dien-3-one);
‘‘(xxiii) methandriol (17α-methyl-3β,17β-dihydroxyandrost-
5-ene);
‘‘(xxiv) methenolone (1-methyl-17β-hydroxy-5α-androst-1-
en-3-one);
‘‘(xxv) 17α-methyl-3β, 17β-dihydroxy-5α-androstane;
‘‘(xxvi) 17α-methyl-3α,17β-dihydroxy-5α-androstane;
‘‘(xxvii) 17α-methyl-3β,17β-dihydroxyandrost-4-ene.
‘‘(xxviii) 17α-methyl-4-hydroxynandrolone (17α-methyl-4-
hydroxy-17β-hydroxyestr-4-en-3-one);
‘‘(xxix) 
methyldienolone 
(17α-methyl-17β-hydroxyestra-
4,9(10)-dien-3-one);
‘‘(xxx) methyltrienolone (17α-methyl-17β-hydroxyestra-4,9-
11-trien-3-one);
‘‘(xxxi) 
methyltestosterone 
(17α-methyl-17β-
hydroxyandrost-4-en-3-one);
‘‘(xxxii) mibolerone (7α,17α-dimethyl-17β-hydroxyestr-4-en-
3-one);
‘‘(xxxiii) 17α-methyl->1-dihydrotestosterone (17β-hydroxy-
17α-methyl-5α-androst-1-en-3-one) (a.k.a. ‘17-α-methyl-1-testos-
terone’);
‘‘(xxxiv) nandrolone (17β-hydroxyestr-4-en-3-one);
‘‘(xxxv) norandrostenediol—
‘‘(I) 19-nor-4-androstenediol (3β, 17β-dihydroxyestr-4-
ene);
‘‘(II) 19-nor-4-androstenediol (3α, 17β-dihydroxyestr-4-
ene);
‘‘(III) 19-nor-5-androstenediol (3β, 17β-dihydroxyestr-
5-ene); and
‘‘(IV) 19-nor-5-androstenediol (3α, 17β-dihydroxyestr-
5-ene);
‘‘(xxxvi) norandrostenedione—
VerDate 11-MAY-2000
08:28 Nov 10, 2005
Jkt 029194
PO 00000
Frm 00526
Fmt 6580
Sfmt 6581
C:\STATUTES\2004\29194PT2.001
APPS10
PsN: 29194PT2
118 STAT. 1663
PUBLIC LAW 108–358—OCT. 22, 2004
‘‘(I) 
19-nor-4-androstenedione 
(estr-4-en-3,17-dione);
and
‘‘(II) 19-nor-5-androstenedione (estr-5-en-3,17-dione;
‘‘(xxxvii) norbolethone (13β,17α-diethyl-17β-hydroxygon-4-
en-3-one);
‘‘(xxxviii) 
norclostebol 
(4-chloro-17β-hydroxyestr-4-en-3-
one);
‘‘(xxxix) norethandrolone (17α-ethyl-17β-hydroxyestr-4-en-
3-one);
‘‘(xl) normethandrolone (17α-methyl-17β-hydroxyestr-4-en-
3-one);
‘‘(xli) 
oxandrolone 
(17α-methyl-17β-hydroxy-2-oxa-[5α]-
androstan-3-one);
‘‘(xlii) oxymesterone (17α-methyl-4,17β-dihydroxyandrost-4-
en-3-one);
‘‘(xliii) oxymetholone (17α-methyl-2-hydroxymethylene-17β-
hydroxy-[5α]-androstan-3-one);
‘‘(xliv) stanozolol (17α-methyl-17α-hydroxy-[5α]-androst-2-
eno[3,2-c]-pyrazole);
‘‘(xlv) stenbolone (17β-hydroxy-2-methyl-[5α]-androst-1-en-
3-one);
‘‘(xlvi) testolactone (13-hydroxy-3-oxo-13,17-secoandrosta-
1,4-dien-17-oic acid lactone);
‘‘(xlvii) testosterone (17β-hydroxyandrost-4-en-3-one);
‘‘(xlviii) 
tetrahydrogestrinone 
(13β,17α-diethyl-17β-
hydroxygon-4,9,11-trien-3-one);
‘‘(xlix) trenbolone (17β-hydroxyestr-4,9,11-trien-3-one); and
‘‘(xlx) any salt, ester, or ether of a drug or substance
described in this paragraph.
The substances excluded under this subparagraph may at any time
be scheduled by the Attorney General in accordance with the
authority and requirements of subsections (a) through (c) of section
201.’’; and
(2) in paragraph (44), by inserting ‘‘anabolic steroids,’’ after
‘‘marihuana,’’.
(b) AUTHORITY
AND CRITERIA
FOR CLASSIFICATION.—Section
201(g) of the Controlled Substances Act (21 U.S.C. 811(g)) is
amended—
(1) in paragraph (1), by striking ‘‘substance from a schedule
if such substance’’ and inserting ‘‘drug which contains a con-
trolled substance from the application of titles II and III of
the Comprehensive Drug Abuse Prevention and Control Act
(21 U.S.C. 802 et seq.) if such drug’’; and
(2) in paragraph (3), by adding at the end the following:
‘‘(C) Upon the recommendation of the Secretary of Health
and Human Services, a compound, mixture, or preparation
which contains any anabolic steroid, which is intended for
administration to a human being or an animal, and which,
because of its concentration, preparation, formulation or
delivery system, does not present any significant potential for
abuse.’’.
(c) ANABOLIC STEROIDS CONTROL ACT.—Section 1903 of the
Anabolic Steroids Control Act of 1990 (Public Law 101–647) is
amended—
(1) by striking subsection (a); and
(2) by redesignating subsections (b) and (c) as subsections
(a) and (b), respectively.
21 USC 802 note.
VerDate 11-MAY-2000
08:28 Nov 10, 2005
Jkt 029194
PO 00000
Frm 00527
Fmt 6580
Sfmt 6581
C:\STATUTES\2004\29194PT2.001
APPS10
PsN: 29194PT2
118 STAT. 1664
PUBLIC LAW 108–358—OCT. 22, 2004
(d) EFFECTIVE DATE.—The amendments made by this section
shall take effect 90 days after the date of enactment of this Act.
SEC. 3. SENTENCING COMMISSION GUIDELINES.
The United States Sentencing Commission shall—
(1) review the Federal sentencing guidelines with respect
to offenses involving anabolic steroids;
(2) consider amending the Federal sentencing guidelines
to provide for increased penalties with respect to offenses
involving anabolic steroids in a manner that reflects the serious-
ness of such offenses and the need to deter anabolic steroid
trafficking and use; and
(3) take such other action that the Commission considers
necessary to carry out this section.
SEC. 4. PREVENTION AND EDUCATION PROGRAMS.
(a) IN GENERAL.—The Secretary of Health and Human Services
(referred to in this Act as the ‘‘Secretary’’) shall award grants
to public and nonprofit private entities to enable such entities
to carry out science-based education programs in elementary and
secondary schools to highlight the harmful effects of anabolic
steroids.
(b) ELIGIBILITY.—
(1) APPLICATION.—To be eligible for grants under subsection
(a), an entity shall prepare and submit to the Secretary an
application at such time, in such manner, and containing such
information as the Secretary may require.
(2) PREFERENCE.—In awarding grants under subsection (a),
the Secretary shall give preference to applicants that intend
to use grant funds to carry out programs based on—
(A) the Athletes Training and Learning to Avoid
Steroids program;
(B) The Athletes Targeting Healthy Exercise and
Nutrition Alternatives program; and
(C) other programs determined to be effective by the
National Institute on Drug Abuse.
(c) USE OF FUNDS.—Amounts received under a grant under
subsection (a) shall be used for education programs that will directly
communicate with teachers, principals, coaches, as well as
elementary and secondary school children concerning the harmful
effects of anabolic steroids.
(d) AUTHORIZATION OF APPROPRIATIONS.—There is authorized
to be appropriated to carry out this section, $15,000,000 for each
of fiscal years 2005 through 2010.
SEC. 5. NATIONAL SURVEY ON DRUG USE AND HEALTH.
(a) IN GENERAL.—The Secretary of Health and Human Services
shall ensure that the National Survey on Drug Use and Health
includes questions concerning the use of anabolic steroids.
42 USC
290aa–4 note.
Grants.
42 USC
290bb–25f.
28 USC 994 note.
21 USC 802 note.
VerDate 11-MAY-2000
08:28 Nov 10, 2005
Jkt 029194
PO 00000
Frm 00528
Fmt 6580
Sfmt 6581
C:\STATUTES\2004\29194PT2.001
APPS10
PsN: 29194PT2
118 STAT. 1665
PUBLIC LAW 108–358—OCT. 22, 2004
LEGISLATIVE HISTORY—S. 2195 (H.R. 3866):
HOUSE REPORTS: No. 108–461, Pt. 1 (Comm. on the Judiciary) and Pt. 2 (Comm.
on Energy and Commerce), both accompanying H.R. 3866.
CONGRESSIONAL RECORD, Vol. 150 (2004):
Oct. 6, considered and passed Senate.
Oct. 8, considered and passed House.
(b) AUTHORIZATION OF APPROPRIATIONS.—There is authorized
to be appropriated to carry out this section, $1,000,000 for each
of fiscal years 2005 through 2010.
Approved October 22, 2004.
VerDate 11-MAY-2000
08:28 Nov 10, 2005
Jkt 029194
PO 00000
Frm 00529
Fmt 6580
Sfmt 6580
C:\STATUTES\2004\29194PT2.001
APPS10
PsN: 29194PT2